查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1465106

色素性视网膜炎市场：按类型、产品、最终用途分类 - 2024-2030 年全球预测

Retinitis Pigmentosa Market by Type (Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, X-linked Retinitis Pigmentosa), Offering (Diagnosis, Treatment), End-use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年视网膜色素变性市场规模为98.5亿美元，预计2024年将达106.6亿美元，2030年将达180.4亿美元，复合年增长率为9.02%。

色素性视网膜炎 (RP) 是一组罕见的遗传性疾病，涉及视网膜细胞的破坏和损失，导致进行性视力丧失。这种疾病影响着全世界约四千分之一的人，是眼科和基因研究领域的一个主要问题。在意识提高、基因检测进步和治疗性介入开发的推动下，RP 治疗和管理市场正在经历适度增长。然而，新的治疗方法面临着高成本、治疗选择有限以及导致 RP 的基因突变的复杂性等挑战。正在进行的旨在了解 RP 遗传基础和开发标靶治疗的研究和试验为患者提供了充满希望的未来。此外，政府和组织加强对罕见疾病研究和资助的力度也预计将显着提振市场。此外，治疗色素性视网膜炎的持续治疗和诊断进展正在创造市场成长机会。

主要市场统计
基准年[2023] 98.5亿美元
预测年份 [2024] 106.6亿美元
预测年份 [2030] 180.4亿美元
复合年增长率（%） 9.02%

类型：由于体染色体显性遗传，色素性视网膜炎病例迅速增加

体染色体显性视网膜色素变性（adRP）是一种体染色体显性遗传疾病。这意味着这种疾病有 50% 的机会从受影响的父母传染给他们的孩子。患有 adRP 的人在与其病情相关的基因之一中存在足够多的突变，导致疾病显现。症状通常出现在成年早期，包括夜盲症、视野狭窄和周边视力逐渐丧失。色素性视网膜炎（arRP）是一种体染色体隐性遗传疾病，需要遗传两个突变基因。这种形式的色素性视网膜炎比体染色体显性遗传的色素性视网膜炎不太常见，因为父母双方具有相同基因突变的机会较低。受 arRP 影响的个体通常会出现与受 adRP 影响相似的症状，但发病却截然不同。患有arRP的人的父母通常是突变基因的一个拷贝的携带者，儘管他们本身不受影响。 X 连锁色素性视网膜炎 (XLRP) 是一种罕见的色素性视网膜炎，透过 X 染色体遗传。这种遗传模式意味着它在只有一条 X 染色体的男性中更为常见。拥有两条 X 染色体的女性不太容易感染这种疾病，而且症状通常较轻微。 XLRP 通常始于儿童，且比其他色素性视网膜炎进展得更快。基因突变会影响视网膜感光细胞，导致进行性视力丧失。

最终用途：扩大专科诊所治疗和管理色素性视网膜炎的机会

居家照护为色素性视网膜炎 (RP) 患者提供舒适的家中医疗和支持性护理。这种护理的重点是透过个人化的治疗计划最大限度地提高 RP 患者的生活质量，包括医疗保健专业人员的定期监测、视觉辅助设备的指导以及日常生活活动的帮助。居家照护对于确保持续的照护和支持至关重要，特别是在晚期，患者可能会出现严重的视力丧失。医院在色素性视网膜炎的诊断、治疗和管理中发挥重要作用。这包括从基因检测和咨询到先进治疗性介入的综合服务。该医院设有专门的眼科部门，并提供多学科的 RP 护理方法，结合最新的研究成果和治疗方法。医院治疗对于需要手术和全身干预的复杂病例的初步诊断和治疗至关重要。专科诊所是专门治疗和管理特定疾病（包括色素性视网膜炎）的机构。这些诊所通常提供一般诊所无法提供的专业治疗，包括接触具有深厚 RP 专业知识的眼科医师。我们的专科诊所提供先进的诊断服务、量身定制的治疗计划以及 RP 研究前沿的创新治疗方法。这对于寻求专业治疗并可能受益于尖端治疗方法的患者至关重要。

区域洞察

在美洲，色素性视网膜炎 (RP) 正在透过大量的研发投资来解决。 FDA 已核准了多种旨在控制症状和减缓 RP 进展的治疗方法和设备。最近关于基因疗法和植入式设备的专利显示出作为未来治疗方法的希望。获得 RP 治疗至关重要，因为消费者对 RP 治疗的认识和支出很高，并且有保险承保。该国的全民健保系统确保治疗相对容易，从而影响对 RP 管理的产品和服务的积极购买行为。在亚太地区，由于政府措施和私人投资，RP 的研究和治疗方案正在迅速增加。亚太地区的消费者越来越意识到并愿意投资基因检测和新治疗方法，但农村地区的可近性仍然是一个问题。政府和非政府组织积极资助 RP 研究并支持社区意识提升计划。欧盟对 RP 采取协作方式，多个国家参与跨国研究计画。基因治疗和视网膜植入的进展值得注意，欧盟法规结构正在发挥支持作用。欧盟的消费者医疗保健支出受到涵盖 RP 各种治疗的公共卫生系统可用性的影响。在中东，人们对包括 RP 在内的遗传疾病越来越感兴趣，沙乌地阿拉伯和阿拉伯联合大公国等国家投资于医疗基础设施和研究。文化因素和医疗保健政策影响消费者对 RP 治疗的态度，导致采用先进医疗解决方案的趋势日益增强。非洲的情况很复杂，都市区地区在获得永久居民待遇方面存在巨大差异。国际组织为改善医疗保健服务所做的努力以及非洲各国政府为提高对遗传疾病的认识所做的努力至关重要。 RP 治疗市场正在逐渐发展，重点是经济实惠的解决方案。

FPNV定位矩阵

FPNV 定位矩阵对于评估视网膜色素变性市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对视网膜色素变性市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.视网膜色素变性市场的市场规模与预测是多少？

2.在视网膜色素变性市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.视网膜色素变性市场的技术趋势和法规结构是什么？

4.视网膜色素变性市场主要供应商的市场占有率为何？

5. 进入视网膜色素变性市场合适的形式和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球范围内影响视网膜的罕见眼科疾病率不断上升
      • 越来越重视基因治疗和个人化医疗
    • 抑制因素
      • 色素性视网膜炎所需治疗的可近性和可负担性
    • 机会
      • 支持政府核准新开发的治疗色素性视网膜炎的药物
      • 视网膜色素变性治疗和诊断的持续进展
    • 任务
      • 对疾病缺乏认识与误诊
  • 市场区隔分析
    • 类型：体染色体显性遗传性色素性视网膜炎导致色素性视网膜炎病例迅速增加
    • 最终用途：治疗和管理色素性视网膜炎的专业诊所用途的演变
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章色素性视网膜炎市场：依类型

  • 体染色体显性遗传性视网膜色素变性
  • 体染色体隐性遗传色素性视网膜炎
  • X连锁色素性视网膜炎

第七章视网膜色素变性市场：透过提供

  • 诊断
  • 治疗

第 8 章色素性视网膜炎市场：依最终用途

  • 居家护理
  • 医院
  • 专科诊所

第九章美洲视网膜色素变性市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太视网膜色素变性市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲视网膜色素变性市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 市场占有率分析（2023）
  • FPNV 定位矩阵（2023）
  • 竞争情境分析
    • jCyte 的 jCell 疗法进入色素性视网膜炎的 3 期试验
    • 杨森从 MeiraGTx 获得开创性 XLRP 基因疗法的权利，以加速视网膜疾病的进展
    • RD 基金会支持 NVAsc 视网膜治疗的突破性进展
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-7A1CEDCFE674

[188 Pages Report] The Retinitis Pigmentosa Market size was estimated at USD 9.85 billion in 2023 and expected to reach USD 10.66 billion in 2024, at a CAGR 9.02% to reach USD 18.04 billion by 2030.

Retinitis Pigmentosa (RP) is a set of rare genetic conditions that involve a breakdown and loss of cells in the retina, leading to progressive vision loss. This condition affects approximately 1 in 4,000 people globally, making it a significant concern in the ophthalmological and genetic research sectors. The RP treatment and management market is witnessing gradual growth, spurred by rising awareness, advancements in genetic testing, and the development of therapeutic interventions. However, the market faces challenges such as the high cost of emerging therapies, limited availability of treatment options, and the complexity of the genetic mutations leading to RP. The ongoing research and trials aiming to understand the genetic basis of RP and to develop targeted treatments offer a promising future for patients. Moreover, growing initiatives by governments and organizations for rare disease research and funding are expected to boost the market significantly. Furthermore, ongoing treatment and diagnostics advancements to treat retinitis pigmentosa create opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 9.85 billion
Estimated Year [2024] USD 10.66 billion
Forecast Year [2030] USD 18.04 billion
CAGR (%) 9.02%

Type: Burgeoning cases of retinitis pigmentosa due to autosomal dominant retinitis pigmentosa

Autosomal dominant retinitis pigmentosa (adRP) is a genetic condition that ensues an autosomal dominant inheritance pattern. This means the disease is passed down from an affected parent to their child, with a 50% chance of inheritance. Individuals with adRP have a mutation in one of the genes associated with the condition, sufficient for the disease to manifest. Symptoms often appear in early adulthood and may include night blindness, tunnel vision, and a gradual progression to loss of peripheral vision. Autosomal recessive retinitis pigmentosa (arRP) needs the inheritance of two mutated genes for the disease to manifest in the offspring. This form of Retinitis Pigmentosa is thus less common than its autosomal dominant counterpart, given the lower probability of both parents carrying the same genetic mutations. Individuals affected by arRP typically experience similar symptoms to those with adRP, but the onset can vary widely. Parents of an individual with arRP are usually not affected themselves, but they are carriers of one copy of the mutated gene. X-linked retinitis pigmentosa (XLRP) is a rare form of Retinitis Pigmentosa transmitted through the X chromosome. This mode of inheritance means that the disease predominantly affects males with only one X chromosome. Females with two X chromosomes are less likely to be involved and often exhibit milder symptoms if they manifest the condition. XLRP is characterized by an early onset, usually in childhood, and tends to progress more rapidly than other forms of retinitis pigmentosa. The genetic mutation affects the retinal photoreceptor cells, leading to progressive vision loss.

End-use: Evolving utilization of specialty clinics for the treatment and management of retinitis pigmentosa

Homecare involves providing medical and supportive care to patients with Retinitis Pigmentosa (RP) in the comfort of their homes. This focuses on maximizing the quality of life for individuals with RP through personalized treatment plans, including regular monitoring by healthcare professionals, guidance on visual aids, and assistance in daily activities. The homecare setting is vital for ensuring continuous care and support, especially in the advanced stages of the condition, where patients may experience significant vision loss. Hospitals play a crucial role in diagnosing, treating, and managing Retinitis Pigmentosa. This involves comprehensive services that range from genetic testing and counseling to advanced therapeutic interventions. Hospitals have specialized ophthalmology departments that offer a multidisciplinary approach to RP care, incorporating the latest research findings and treatment modalities. The hospital setting is essential for the initial diagnosis and managing complex cases requiring surgical or systemic interventions. Specialty Clinics are dedicated facilities that focus on treating and managing specific disorders, including Retinitis Pigmentosa. These clinics often provide access to specialized care not available in general practice settings, including access to ophthalmologists with deep expertise in RP. Specialty clinics offer advanced diagnostic services, tailor-made treatment plans, and innovative therapies that are at the forefront of RP research. This is crucial for patients seeking expert management of their condition and for those who may benefit from cutting-edge treatment options.

Regional Insights

In the Americas, the Retinitis Pigmentosa (RP) is addressed with significant investments in research and development. The FDA has approved several treatments and devices designed to manage symptoms or slow the progression of RP. Recent patents in gene therapy and implantable devices show promise for future treatments. Consumer awareness and spending on RP treatments are high, with insurance coverage crucial in accessibility. The country's universal healthcare system ensures that treatments are relatively accessible, influencing positive purchasing behaviors toward RP management products and services. Asia-Pacific is witnessing a rapid increase in RP research and treatment options, driven by government initiatives and private investments. Asia-Pacific consumers have shown a growing awareness and willingness to invest in genetic testing and novel treatments, although accessibility issues remain in rural areas. The government and NGOs actively fund RP research and support community awareness programs. The EU has a coordinated approach to RP, with multiple countries participating in cross-border research initiatives. Advances in gene therapy and retinal implants are notable, with the EU regulatory framework playing a supportive role. Consumer healthcare spending in the EU is influenced by the availability of public healthcare systems, which cover a range of treatments for RP. There is a growing interest in genetic disorders, including RP, in the Middle East, with Saudi Arabia and the United Arab Emirates countries investing in healthcare infrastructure and research. Cultural factors and healthcare policies impact consumer attitudes toward RP treatments, with an increasing trend toward adopting advanced medical solutions. Africa presents a complex picture, with a vast discrepancy in access to RP treatments between urban and rural areas. Efforts by international organizations to improve healthcare access and initiatives by African governments to enhance genetic disorder awareness are crucial. The market for RP treatments is gradually evolving, with an emphasis on affordable solutions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Retinitis Pigmentosa Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Retinitis Pigmentosa Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Retinitis Pigmentosa Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Astellas Pharma Inc., Beacon Therapeutics Limited, BIOGEN INC., Clino Corporation, Coave Therapeutics SA, Editas Medicine, Inc., GENSIGHT BIOLOGICS, Genethon, Johnson & Johnson Services, Inc., MeiraGTx Holdings PLC, Mimetogen Pharmaceuticals, Nacuity Pharmaceuticals, Inc., Novartis AG, Orphagen Pharmaceuticals, Inc., Oxford Biomedica PLC, Precision BioSciences, Inc., ProQR Therapeutics N.V., Sanofi S.A., Santen Pharmaceutical Co., Ltd., Spark Therapeutics, Inc., Sun Pharmaceutical Industries Ltd., and The Wyanoke Group.

Market Segmentation & Coverage

This research report categorizes the Retinitis Pigmentosa Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Autosomal Dominant Retinitis Pigmentosa
    • Autosomal Recessive Retinitis Pigmentosa
    • X-linked Retinitis Pigmentosa
  • Offering
    • Diagnosis
    • Treatment
  • End-use
    • Homecare
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Retinitis Pigmentosa Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Retinitis Pigmentosa Market?

3. What are the technology trends and regulatory frameworks in the Retinitis Pigmentosa Market?

4. What is the market share of the leading vendors in the Retinitis Pigmentosa Market?

5. Which modes and strategic moves are suitable for entering the Retinitis Pigmentosa Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of rare eye diseases affecting retina worldwide
      • 5.1.1.2. Growing emphasis on genetic therapies and personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Accessibility and affordability of treatments required for retinitis pigmentosa
    • 5.1.3. Opportunities
      • 5.1.3.1. Supportive government approvals for newly developed drugs to treat retinitis pigmentosa
      • 5.1.3.2. Ongoing treatment and diagnostics advancements to treat retinitis pigmentosa
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness and misdiagnosis of the condition
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Burgeoning cases of retinitis pigmentosa due to autosomal dominant retinitis pigmentosa
    • 5.2.2. End-use: Evolving utilization of specialty clinics for the treatment and management of retinitis pigmentosa
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Retinitis Pigmentosa Market, by Type

  • 6.1. Introduction
  • 6.2. Autosomal Dominant Retinitis Pigmentosa
  • 6.3. Autosomal Recessive Retinitis Pigmentosa
  • 6.4. X-linked Retinitis Pigmentosa

7. Retinitis Pigmentosa Market, by Offering

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Treatment

8. Retinitis Pigmentosa Market, by End-use

  • 8.1. Introduction
  • 8.2. Homecare
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Retinitis Pigmentosa Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Retinitis Pigmentosa Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Retinitis Pigmentosa Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. jCyte's jCell Therapy Enters Phase 3 Trials for Retinitis Pigmentosa
    • 12.3.2. Janssen Acquires Rights to Pioneering XLRP Gene Therapy from MeiraGTx, Catalyzing Advancements in Retinal Diseases
    • 12.3.3. The RD Fund Backs NVasc's Breakthrough in Retinal Therapeutics
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. RETINITIS PIGMENTOSA MARKET RESEARCH PROCESS
  • FIGURE 2. RETINITIS PIGMENTOSA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. RETINITIS PIGMENTOSA MARKET DYNAMICS
  • FIGURE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RETINITIS PIGMENTOSA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 283. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023